Trials / Unknown
UnknownNCT03391739
CART-19 Cells For R/R B-ALL
CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 1 Year – 60 Years
- Healthy volunteers
- Not accepted
Summary
There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CART-19 cells | CART-19 cells treat |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
- First posted
- 2018-01-05
- Last updated
- 2018-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03391739. Inclusion in this directory is not an endorsement.